It was reported that the new type of corona virus vaccine developed by German vaccine manufacturer BioNTech and its US partner Pfizer applied to the European Medicines Agency (EMA) for use in children between the ages of 12 and 15.
In the statement made by the BioNTech company, it was stated that the EMA application was made for children between the ages of 12-15 and the vaccine could be applied in this age group in 27 EU countries if the Agency approved.
In the statement, it was reminded that he has already applied to the US Food and Drug Administration (FDA) for “Emergency Use Permit”.
The company recently announced that the clinical study it conducted on 2 thousand 260 people between the ages of 12 and 15 in the USA showed 100 percent efficiency.
In the statement, it was stated that the side effects would correspond to those in the 16-25 age group.
It was reported that children between the ages of 12-15 in 27 EU countries are planned to be vaccinated in mid-June, if the EMA approves.
EMA WAITING FOR SCIENTIFIC EVALUATIONS
EU officials also stated that they are waiting for the results of scientific evaluations and studies for the application of the BioNTech-Pfizer vaccine to children.
Reminding that they are negotiating to purchase 1.8 billion more doses of BioNTech-Pfizer vaccine for EU countries, Eric Mamer, a spokesperson of the EU Commission, said that they will have enough doses to vaccinate children in case of approval from EMA.
Mamer rejected the criticism that the EU Commission did not take into account the child population within the union’s borders in vaccination.
Download the NTV application, be informed about the developments
VACCINE WILL COME FIRST, THEN TECHNOLOGY